Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...

Prospective clinical trials needed to validate the findings ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Low back pain is a leading global cause of disability, and the musculoskeletal impact of lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) used for coronary heart disease (CHD) prevention has ...

Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...

Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve ...

NEW ORLEANS—Adding the PCSK9 inhibitor evolocumab (Repatha; Amgen) to statin therapy significantly cuts the risk of major cardiovascular events when compared with statins alone in high-risk patients ...

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for ...